ERBB2 and non-small cell lung carcinoma: The phase II HUDSON basket trial investigated the combination of T-DXd and Durvalumab in patients previously treated with anti-PD1/PD-L1 therapy, including those with HER2-mutant (HER2m) and HER2-overexpressed (HER2e) NSCLC.